https://www.selleckchem.com/pr....oducts/thiamet-g.htm
Median [95% confidence interval (CI)] follow-up was 21.9 (1.4-57. months. Median OS and PFS were 15.5 (14.6-19) and 7 (6.1-8.1) months, respectively. Patients with HRD had improved PFS compared with no HRD when treated with first-line (1L) platinum [HR, 0.44 (95% CI 0.29-0.67); P less then 0.01], but not with 1L-non-platinum. Multivariate analysis showed HRD patients had improved OS regardless of their first-line treatment, but most had platinum exposure during their course. Biallelic HRm (11%) and core HRm (12%) had higher genomic
Like
Comment
Share
